Clin2
NCT07029217Possibly a fitRecruiting

Lower radiation dose study for B-cell lymphomas

Follicular LymphomaMarginal Zone Lymphoma

Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.

This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
375 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Diagnosed with follicular lymphoma or marginal zone lymphoma (including related subtypes).
  • Lymphoma is in stage I or II (limited to one or two nearby lymph node areas).
  • You haven't had any treatment for lymphoma yet (newly diagnosed or previously watched).
  • Must be 18 years or older.
  • Able to start radiation therapy within 2 months of joining the study.
  • If you have a stomach MALT lymphoma, you must have tested negative for H. pylori infection in the last 6 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05294731Recruiting· Phase 1/Phase 2
Study drug for certain B-cell cancers in Chinese participants

This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.

Bengbu, Anhui
NCT06704555Recruiting· Phase 2
Radiation plus drug combo for untreated bulky follicular lymphoma

This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.

Tianjin, Tianjin Municipality
NCT05929222Recruiting· Phase 3
Radiation with or without an antibody for early follicular lymphoma

This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.

Sassuolo, Modena (MO)
NCT04669171Recruiting· Phase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined

This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.

Boston, Massachusetts
NCT07725406Not yet recruiting· Phase 1
Low-dose radiation plus CAR T-cell therapy for certain blood cancers

This trial tests whether a low dose of total body radiation combined with CAR T-cell therapy can help people with certain types of lymphoma or multiple myeloma that have come back or stopped responding to other treatments. It may be an option for patients whose cancer is hard to treat with standard therapies.

New York, New York
NCT05929612Recruiting· Phase 2
Low-dose targeted radiation alone for marginal zone lymphoma

This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.

Houston, Texas

Hear when a new Follicular Lymphoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.